Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · Real-Time Price · USD

46.96

-0.33 (-0.70%)

At close: Jun 13, 2025, 4:00 PM

46.01

-0.95 (-2.02%)

After-hours: Jun 13, 2025, 7:13 PM EDT

Kymera Therapeutics Employees

Kymera Therapeutics had 188 employees as of December 31, 2024. The number of employees increased by 1 or 0.53% compared to the previous year.

Employees

188

Change (1Y)

1

Growth (1Y)

0.53%

Revenue / Employee

$313,218

Profits / Employee

-$1,281,287

Market Cap

3.06B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	188	1	0.53%
Dec 31, 2023	187	20	11.98%
Dec 31, 2022	167	26	18.44%
Dec 31, 2021	141	66	88.00%
Dec 31, 2020	75	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

KYMR News

8 days ago - Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial - Barrons
11 days ago - Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data - Seeking Alpha
11 days ago - Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. - Barrons
11 days ago - Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewsWire
14 days ago - Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 - GlobeNewsWire
15 days ago - Kymera Therapeutics to Participate in Upcoming June Investor Conferences - GlobeNewsWire
25 days ago - Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - GlobeNewsWire
4 weeks ago - Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff - Seeking Alpha